{"id":76785,"date":"2026-08-27T14:17:27","date_gmt":"2026-08-27T06:17:27","guid":{"rendered":"https:\/\/flcube.com\/?p=76785"},"modified":"2026-08-27T14:17:28","modified_gmt":"2026-08-27T06:17:28","slug":"nmpa-suspends-sales-and-use-of-pierre-fabres-encorafenib-capsules-over-unapproved-manufacturing-change","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76785","title":{"rendered":"NMPA Suspends Sales and Use of Pierre Fabre&#8217;s Encorafenib Capsules Over Unapproved Manufacturing Change"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>National Medical Products Administration (NMPA)<\/strong> issued a notice ordering the immediate suspension of sales and use of <strong>Encorafenib Capsules<\/strong> (batch numbers <strong>5G2T3<\/strong> and <strong>5G2T4<\/strong>) manufactured by <strong>PIERRE FABRE MEDICAMENT<\/strong>. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) <strong>encorafenib<\/strong> \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from <strong>Good Manufacturing Practice (GMP)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-action-snapshot\" class=\"wp-block-heading\">Regulatory Action Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Regulator<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong><\/td><\/tr><tr><td>Action<\/td><td>Immediate suspension of sales and use<\/td><\/tr><tr><td>Product<\/td><td><strong>Encorafenib Capsules<\/strong> (Registration No.: GYZZ HJ20250082)<\/td><\/tr><tr><td>Manufacturer<\/td><td><strong>PIERRE FABRE MEDICAMENT<\/strong> (France)<\/td><\/tr><tr><td>Affected Batches<\/td><td><strong>5G2T3<\/strong>, <strong>5G2T4<\/strong><\/td><\/tr><tr><td>Violation<\/td><td>Unapproved major API manufacturing change; severe GMP deviations<\/td><\/tr><tr><td>Action Date<\/td><td>26 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-inspection-findings-amp-violations\" class=\"wp-block-heading\">Inspection Findings &amp; Violations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unapproved Manufacturing Change:<\/strong> A major change was made to the manufacturing process of the API encorafenib specified in the registration information, which has not yet been approved<\/li>\n\n\n\n<li><strong>Unauthorized Market Release:<\/strong> The company used this API to produce certain batches of the drug product (batch numbers <strong>5G2T3<\/strong> and <strong>5G2T4<\/strong>) and released them for sale in the Chinese market<\/li>\n\n\n\n<li><strong>Quality System Failures:<\/strong> Change control and batch release review within the company&#8217;s quality management system severely deviated from GMP<\/li>\n\n\n\n<li><strong>Regulatory Basis:<\/strong> The failures constitute non\u2011compliance with China&#8217;s <strong>Good Manufacturing Practice for Drugs (2010 Revision)<\/strong> and its appendices<\/li>\n\n\n\n<li><strong>Inspection Method:<\/strong> The findings stem from a remote inspection organized by the NMPA<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supply Disruption in China:<\/strong> The suspension removes affected batches of encorafenib \u2014 a BRAF\u2011targeted oncology therapy \u2014 from the Chinese market, creating potential treatment access considerations while the matter is resolved.<\/li>\n\n\n\n<li><strong>GMP Enforcement Signal:<\/strong> The decisive action underscores the NMPA&#8217;s zero\u2011tolerance stance on unauthorized post\u2011approval manufacturing changes, reinforcing expectations for rigorous change control across both domestic and overseas suppliers.<\/li>\n\n\n\n<li><strong>Compliance Exposure:<\/strong> For <strong>PIERRE FABRE MEDICAMENT<\/strong>, the notice raises remediation priorities, including change\u2011control validation, batch release review overhauls, and potential follow\u2011up inspections before market restoration.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> The company&#8217;s corrective action plan, any broader batch recalls, NMPA follow\u2011up decisions on the API process change application, and the timeline for resuming normal commercial supply in China.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment, medical, or regulatory advice. Statements regarding remediation and market restoration are forward\u2011looking and subject to risks and uncertainties; actual outcomes may differ materially. Refer to official publications of the NMPA for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[],"class_list":["post-76785","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Suspends Sales and Use of Pierre Fabre&#039;s Encorafenib Capsules Over Unapproved Manufacturing Change - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76785\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Suspends Sales and Use of Pierre Fabre&#039;s Encorafenib Capsules Over Unapproved Manufacturing Change\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76785\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:17:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T06:17:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Suspends Sales and Use of Pierre Fabre&#8217;s Encorafenib Capsules Over Unapproved Manufacturing Change\",\"datePublished\":\"2026-08-27T06:17:27+00:00\",\"dateModified\":\"2026-08-27T06:17:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785\"},\"wordCount\":431,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76785#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76785\",\"name\":\"NMPA Suspends Sales and Use of Pierre Fabre's Encorafenib Capsules Over Unapproved Manufacturing Change - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-27T06:17:27+00:00\",\"dateModified\":\"2026-08-27T06:17:28+00:00\",\"description\":\"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76785\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76785#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Suspends Sales and Use of Pierre Fabre&#8217;s Encorafenib Capsules Over Unapproved Manufacturing Change\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Suspends Sales and Use of Pierre Fabre's Encorafenib Capsules Over Unapproved Manufacturing Change - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76785","og_locale":"en_US","og_type":"article","og_title":"NMPA Suspends Sales and Use of Pierre Fabre's Encorafenib Capsules Over Unapproved Manufacturing Change","og_description":"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).","og_url":"https:\/\/flcube.com\/?p=76785","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:17:27+00:00","article_modified_time":"2026-08-27T06:17:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76785#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76785"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Suspends Sales and Use of Pierre Fabre&#8217;s Encorafenib Capsules Over Unapproved Manufacturing Change","datePublished":"2026-08-27T06:17:27+00:00","dateModified":"2026-08-27T06:17:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76785"},"wordCount":431,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76785#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76785","url":"https:\/\/flcube.com\/?p=76785","name":"NMPA Suspends Sales and Use of Pierre Fabre's Encorafenib Capsules Over Unapproved Manufacturing Change - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-27T06:17:27+00:00","dateModified":"2026-08-27T06:17:28+00:00","description":"The National Medical Products Administration (NMPA) issued a notice ordering the immediate suspension of sales and use of Encorafenib Capsules (batch numbers 5G2T3 and 5G2T4) manufactured by PIERRE FABRE MEDICAMENT. The action follows an NMPA remote inspection that identified an unapproved major change to the manufacturing process of the active pharmaceutical ingredient (API) encorafenib \u2014 used in certain batches already released for sale in the Chinese market \u2014 constituting severe deviations from Good Manufacturing Practice (GMP).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76785#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76785"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76785#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Suspends Sales and Use of Pierre Fabre&#8217;s Encorafenib Capsules Over Unapproved Manufacturing Change"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76785"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76785\/revisions"}],"predecessor-version":[{"id":76786,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76785\/revisions\/76786"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}